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Abstract
Objective The study aim was to evaluate the cost effectiveness and budget impact of siponimod compared to interferon 
beta-1a for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease, from a Swiss health 
insurance perspective.
Methods We conducted an analysis using a Markov cohort model with a cycle length of 1 year, life-long time horizon, and 
discount rate of 3% for cost and health outcomes. We used a matching-adjusted indirect comparison to estimate clinical out-
comes using data from the EXPAND randomised controlled trial of siponimod vs placebo and the Nordic SPMS randomised 
controlled trial of interferon beta-1a vs placebo as the basis for estimates of disability progression and relapse outcomes. 
We used 6-month confirmed disability progression results to estimate disability progression in the base-case analysis. We 
calculated quality-adjusted life-years (QALYs) based on an external study that administered the EQ-5D-3L questionnaire to 
European patients with multiple sclerosis. We included costs (Swiss Franc (CHF), year 2020) of drug acquisition/adminis-
tration, adverse events and disease management. We also performed a budget impact analysis to estimate the cost over the 
first 3 years of introducing siponimod.
Results For the base case, siponimod resulted in mean incremental costs of CHF 84,901 (siponimod: CHF 567,838, interferon 
beta-1a: CHF 482,937) and mean incremental QALYs of 1.591 (siponimod: 7.495, interferon beta-1a: 5.905), leading to an 
incremental cost-effectiveness ratio of CHF 53,364 per QALY gained. In the probabilistic sensitivity analysis, the probabil-
ity of the cost effectiveness of siponimod assuming a willingness-to-pay threshold of CHF 100,000 per QALY gained was 
90%. Siponimod was projected to result in drug administration costs for siponimod of CHF 23,817,856 in the first 3 years 
after introduction, accompanied by large cost offsets in drug acquisition of other multiple sclerosis drugs. Considering drug 
administration, monitoring and adverse event management costs, it was estimated to result in additional healthcare costs in 
Switzerland of CHF 2,177,021.
Conclusions In the base-case analysis, we found that siponimod may be cost effective for treating Swiss adult patients with 
SPMS with active disease. The results of the cost-effectiveness analyses are valid under the assumption that the efficacy of 
siponimod and the comparators on disability progression for the overall SPMS population would be the same in the active 
SPMS population.
Clinical Trial Identifier NCT01665144. This economic evaluation was based on the EXPAND trial.
Extended author information available on the last page of the article
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Key Points 
Siponimod may be cost effective for treating Swiss adult 
patients with secondary progressive multiple sclerosis 
with active disease.
Related uncertainty is unavoidable given the lack of 
head-to-head trials directly comparing siponimod with 
other active treatments.
Siponimod is currently reimbursed as a treatment for 
active secondary progressive multiple sclerosis in Swit-
zerland. In our budget impact analysis, it was projected 
to result in additional healthcare costs in Switzerland of 
Swiss Francs 2,177,021 in the first 3 years after introduc-
tion. A limitation of the budget impact analysis was not 
accounting for disease management and relapse costs.
1 Introduction
Multiple sclerosis (MS) is a chronic inflammatory and neu-
rodegenerative disease of the central nervous system that 
leads to neurological impairment and severe disability [1]. It 
is characterised by damage to the myelin sheaths of neurons 
in the central nervous system and axonal loss, resulting in 
impaired brain, optic nerves and spinal cord function [1].
The majority of patients with MS present with a relaps-
ing-remitting MS (RRMS) course of disease, which is char-
acterised by acute episodes of neurological dysfunction, 
termed relapses, followed by complete or incomplete recov-
ery and periods of clinical stability. Incomplete recovery 
from relapses leads to the accumulation of disability [2]. 
Over time, patients with RRMS may eventually transition to 
a secondary progressive course of disease (SPMS) in which 
they experience sustained progression of disability with or 
without superimposed relapses [3]. Population-based epide-
miological studies to assess the prevalence of SPMS have 
reported a wide range between 7.5 and 41.5% of patients 
with MS across European countries [4, 5]. For Switzerland, 
reports range from 5.7 to 18% in the literature [6, 7] and 
physician feedback suggests that an equal number of patients 
(i.e. between 5.7 and 18%) are in the transition phase from 
RRMS to SPMS. Secondary progressive MS can be further 
classified either into an active or non-active form. Patients 
with active SPMS experience relapses and/or show evidence 
of inflammatory activity in imaging, while patients with 
non-active disease do not [8].
There are several disease-modifying therapies (DMTs) 
currently used in Switzerland to treat SPMS. Interferon 
beta-1a  (Avonex® produced by Biogen AG, or  Rebif® pro-
duced by Merck Schweiz AG) has a first-line indication 
for relapsing SPMS, which excludes patients with active 
SPMS who only show evidence of inflammatory activity 
but no relapses. Interferon beta-1b  (Betaferon® produced 
by Bayer AG) is indicated first line for active and non-
active SPMS. Ocrelizumab  (Ocrevus® produced by Roche 
Pharma AG) is indicated for relapsing MS with active dis-
ease, which indirectly includes patients with SPMS who 
still have relapses and an active disease course [9]. Mitox-
antrone  (Novanton® produced by Meda Pharma GmbH) 
is indicated in SPMS as a second-line therapy for patients 
with rapidly progressing MS [10].
Siponimod  (Mayzent® produced by Novartis Pharma 
AG) is a new DMT available for the first-line treatment 
of patients with active SPMS who do not have the geno-
type CYP2C9*3*3. Siponimod is administered as an oral 
tablet. Siponimod is a new member of a class of orally 
administered compounds, referred to as sphingosine-
1-phosphate receptor modulators. In patients with MS, 
siponimod prevents pathogenic effector lymphocytes 
from accessing their targets in the central nervous system 
[11–14]. In addition, siponimod may have neuroprotective 
effects by directly interfering with ongoing sphingosine-
1-phosphate-mediated astroglial inflammatory processes 
and/or stimulating sphingosine-1-phosphate 5-mediated 
pro-remyelination repair mechanisms [14–17]. In the 
EXPAND randomised controlled trial of 1652 patients 
with SPMS with active or non-active disease, siponimod 
was found, relative to placebo, to result in a statistically 
significant reduction in the risk of 6-month confirmed dis-
ability progression (CDP) [hazard ratio of 0.74; 95% confi-
dence interval (CI) 0.60–0.92], and found to have a similar 
safety profile to other drugs in the class [18]. For the active 
SPMS subgroup, the hazard ratio for this reduction was 
estimated at 0.64 (95% CI 0.47–0.86). Six-month CDP was 
defined as a 1-point increase in the Expanded Disability 
Status Scale (EDSS) score if the baseline EDSS score was 
3.0–5.0, or a 0.5-point EDSS score increase if the baseline 
EDSS score was 5.5–6.5, and the increase in EDSS has to 
be confirmed at a scheduled visit at least 6 months apart 
[18]. It was also found in the EXPAND trial that siponi-
mod, relative to placebo, resulted in a statistically sig-
nificant reduction in the annualised relapse rate (rate ratio 
of 0.45; 95% CI 0.34–0.59; risk reduction 55%) [18] for 
the overall EXPAND population, as well as for the active 
SPMS subgroup (rate ratio of 0.40; 95% CI 0.24–0.66; 
risk reduction 60%). Five-year follow-up results from the 
EXPAND trial have demonstrated that early initiation of 
siponimod treatment significantly reduces 6-month CDP 
and the rate of relapses for the overall SPMS population 
in the long term, as detailed in an abstract for the journal 
Neurology [19].
Cost Effectiveness of Siponimod vs Interferon Beta-1a in Adult Patients with Active SPMS
The aim of this study was to assess the cost effectiveness 
of a siponimod treatment strategy compared to interferon 
beta-1a treatment strategy, for adult patients with SPMS 
with active disease in Switzerland. We also assessed the 
budget impact of introducing siponimod for the treatment 
of active SPMS.
2  Methods
We used a Markov cohort model for our cost-effectiveness 
analysis, and an incremental cost per quality-adjusted life-
year (QALY) gained and per life-year (LY) gained approach. 
We built and implemented the Markov cohort model using 
Microsoft Excel 2010. For the base-case analysis, we used 
a time horizon of age 100 years (interpreted as life-long), a 
cycle length of 1 year, and a discount rate of 3% for costs 
and health outcomes (QALYs and LYs). Although there are 
no formal guidelines specifying what discount rate should 
be used for cost-utility analyses in Switzerland, a discount 
rate of 3% per year is generally accepted. We assessed costs 
from a Swiss health insurance system perspective for the 
main analysis and from an approximated societal perspective 
in a secondary analysis. We selected sources for Swiss unit 
costs such as national tariff lists and national statistical data 
based on institutional knowledge. We undertook a series of 
targeted literature searches on PubMed and Google to iden-
tify relevant local parameter values for the models (e.g. “cost 
multiple sclerosis Switzerland”, “utility multiple sclerosis 
Switzerland”).
2.1  Model Structure and Population
For the cost-effectiveness part, we implemented a Markov 
cohort model based on EDSS scores that measure the degree 
of disability in MS on a progressive scale from 0 (indicating 
normal neurological exam and no disability) to 10 (indicat-
ing death due to MS) (Fig. 1). During each model cycle, 
patients in an EDSS-based state could either remain in the 
same EDSS state, transition to a different EDSS state or tran-
sition to the death state. Patients who transition to a differ-
ent EDSS state in a model cycle can either move to a better 
EDSS state (one or more steps) or a worse EDSS state (one 
or more steps). Besides transitioning between model states, 
in each model cycle, patients could also simultaneously 
experience a relapse event and/or discontinue DMT. Once a 
patient discontinued siponimod/interferon beta-1a treatment, 
this discontinuation was assumed to be permanent. Patients 
who discontinued treatment followed transitions of patients 
receiving best supportive care. During each 1-year cycle of 
the model, patients accrued costs and outcomes based on the 
state they had transitioned into from the previous cycle, as 
well as the occurrence of relapse events and whether they 
had already discontinued treatment.
Characteristics of the cohort at the start of the model 
were assumed to match the baseline characteristics of the 
Fig. 1  Structure of the Markov model. A proportion of patients will 
remain in the same Expanded Disability Status Scale (EDSS) state at 
the end of a model cycle. Patients who transition to a different EDSS 
state in a model cycle can either move to a better EDSS state (one or 
more steps) or a worse EDSS state (one or more steps). Transition 
probabilities are specified in Appendix A1 of the ESM. In each of the 
EDSS states, patients may experience a relapse during a model cycle
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EXPAND trial participants with active SPMS. These char-
acteristics were: having active SPMS, an EDSS score of > 1 
and < 8, and not having the genotype CYP2C9*3*3. Fur-
thermore, participants were 64% female, had a mean age of 
46.6 years, mean weight of 70.3 kg, mean time since MS 
diagnosis of 11.1 years, and mean time since SPMS diag-
nosis of 2.9 years.
2.2  Intervention and Comparator
The siponimod treatment strategy comprised siponimod 
and best supportive care (BSC). The comparator strategy 
comprised interferon beta-1a (Rebif 22 µg dose three times 
a week) and BSC, which was selected as the comparator as 
interferon beta-1a is one of few first-line SPMS drugs for 
active disease approved in Switzerland. Published match-
ing-adjusted indirect comparison (MAIC) results for this 
comparison were available [20]. In a scenario analysis, we 
used other approved SPMS drugs for active disease in Swit-
zerland as the comparators (interferon beta-1b plus BSC; 
natalizumab plus BSC). Natalizumab  (Tysabri®, produced 
by Biogen AG) is not indicated for SPMS in Switzerland, 
but it was included as a comparator in a scenario analysis 
because it was tested in a recent clinical trial in an SPMS 
population that allowed MAIC, as reported by Samjoo et al. 
[20].
Siponimod (and BSC) is contraindicated for patients with 
genotype CYP2C9*3*3, administered as a daily 1-mg dose 
for genotype CYP2C9*2*3 or *1*3, and administered as a 
daily 2-mg dose for all other genotypes. Interferon beta-1a is 
administered as a 22-µg dose three times a week. Discontin-
uation of siponimod/interferon beta-1a was assumed to occur 
when the patient’s EDSS score reaches seven or higher.
Background therapy in addition to siponimod or DMT 
is considered in the model as BSC and is assumed to be 
the same in both strategies. In this analysis, background 
therapies used for Swiss patients with MS included corti-
costeroids, symptomatic prescription drugs, over-the-counter 
drugs and other types of medication, as published by Cala-
brese et al. [21]
2.3  Natural History
We calculated transition probabilities between EDSS (and 
death) states used for the model based on data from the pla-
cebo arm of the EXPAND trial [18]. The transition probabil-
ity matrix was generated through a multi-state model (MSM) 
approach (using the “MSM” package in R), in line with the 
natalizumab National Institute for Health and Care Excel-
lence (NICE) manufacturer submission (TA127 [22]). A 
MSM was fitted for patients randomised to the placebo arm 
of the EXPAND trial by utilising information on the EDSS 
state at each scheduled visit, duration spent in each EDSS 
state and initial values of the transition intensity matrix. We 
use data from an observational dataset (the London Ontario 
MS dataset [23]) to calculate certain transition probabili-
ties where it we identified the sample size in the EXPAND 
placebo arm was insufficient to reliably estimate [additional 
information on the method used to club EXPAND and Lon-
don Ontario data are presented in Appendix A1 of the Elec-
tronic Supplementary Material (ESM)].
The MSM transition probability matrix derived from 
EXPAND data was validated by comparing patient distri-
bution by EDSS state using MSM and EXPAND observed 
data after 1 and 2 years. We used data from participants with 
active SPMS in the EXPAND placebo arm as the basis for 
calculating underlying annual relapse rates for EDSS states 
3–7. We assumed that the annual relapse rates for EDSS 
scores 8 and 9 would be the same as for an EDSS score of 
7, and used rate estimates from external studies for EDSS 
scores 0–2 [22, 24].
Background mortality was considered in the analysis by 
using age-specific and sex-specific mortality rates obtained 
from the Swiss Federal Statistical Office [25]. The excess 
mortality associated with MS was incorporated into the 
analysis using EDSS-specific mortality multiplication fac-
tors provided by Pokorski (Table 1) [26].
2.4  Effectiveness Estimates
All underlying transition probabilities are presented in 
Appendix A1 of the ESM, and were categorised to disabil-
ity progression (transitions to a higher EDSS health state) 
and no disability progression (transitions to same or lower 
EDSS health state). We subsequently calculated treatment-
adjusted transition probabilities for each EDSS-based health 
state (additional information on the method used to calculate 
treatment-adjusted transition probabilities are presented in 
Appendix A2 of the ESM). These were calculated based on 
the following formulae and applied in the model:
1. T r e a t m e n t - a d j u s t e d  d i s a b i l i t y  p r o g r e s -
sion = 1− (1 − sum of all disability progression transition 
probabilities)^hazard rate of 6-month CDP for treatment 
vs placebo
2. Treatment-adjusted no disability progression = 1 − treat-
ment-adjusted disability progression
We incorporated hazard, relapse and discontinua-
tion rates for the intervention and comparator strategies 
in the model. We estimated hazard and relapse rates for 
siponimod and interferon beta-1a using MAICs from the 
EXPAND and Nordic SPMS trials, respectively [20]. We 
used hazard rates for 6-month CDP to adjust the transition 
probabilities described in the previous section. We esti-
mated these to be 0.48 for siponimod relative to placebo, 
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and 1.13 for interferon beta-1a relative to placebo. It was 
considered more appropriate to use 6-month CDP for the 
base-case analysis. As the time taken to recover from a 
relapse varies and people may not recover after a relapse 
after 3 months, 6-month CDP is used in clinical practice as 
a more robust measure of permanent disability progression 
compared to 3-month CDP [27].
The estimated annual relative risk of relapse was 0.50 
for siponimod vs placebo and 0.69 for interferon beta-
1a vs placebo. Annual treatment discontinuation rates 
were assumed to be constant over time. For siponimod, it 
was estimated to be 6.37% based on EXPAND trial data 
(siponimod arm only) [18]. For interferon beta-1a, an 
annual treatment discontinuation rate of 9.16% was esti-
mated by dividing the siponimod discontinuation rate of 
6.37%, by the relative risk of discontinuation for siponi-
mod vs interferon beta-1a of 0.695, which was estimated 
through an indirect treatment comparison using SPEC-
TRIMIS trial data [28]. For scenario analyses that used 
alternative model comparators, the same procedure was 
adopted for obtaining effectiveness parameters; which 
resulted in estimates derived from the North American 
study for interferon beta-1b plus BSC, and from the 
ASCEND trial for natalizumab plus BSC (Table 2) [20].
2.5  EQ‑5D Scores
We included European Quality of Life-5 Dimensions (EQ-
5D) scores in the analysis to represent health-related quality 
of life. Although utility values are available from partici-
pants of the EXPAND trial, these were not used because 
there were fewer or no patients with EDSS states 0, 1, 2, 
8 and 9, in the EXPAND trial. During each model cycle, 
patients were assigned an EQ-5D score based on their EDSS 
score, taken from a pooled sample of European patients with 
MS analysed by Kobelt et al. [29]. For the EQ-5D scores of 
patients who were alive, their EQ-5D score was subsequently 
inflated by 0.034 to adjust for the higher EQ-5D score of 
Swiss patients with MS relative to European patients with 
MS illustrated by Kobelt et al., and then reduced by 0.045 to 
adjust for the lower health status of patients with SPMS rela-
tive to general patients with MS as suggested by Orme et al. 
[30]. No further adjustment was incorporated with regard 
to active SPMS because of a lack of information. During 
each model cycle, a proportion of patients in each treatment 
strategy experienced a relapse or specific adverse event. 
The reduction in EQ-5D score associated with a relapse of 
0.076 for a duration of 45 days was applied, obtained from 
an analysis of EXPAND trial data [18]. The reduction asso-
ciated with each type of adverse event used for the model is 
specified in Table A3-2 of the ESM; primarily taken from a 
NICE technology appraisal for ocrelizumab [27].
2.6  Resource Use and Cost Inputs
All cost estimates obtained before 2020 were adjusted by 
inflation to 2020 values using the Swiss consumer price 
index [31].
Table 2  Model input parameters related to clinical effectiveness
BSC best supportive care, MAIC matching-adjusted indirect comparison
a Base-case comparator is interferon beta-1a
b For the probabilistic sensitivity analysis, we used log-normal distributions for the hazard ratios and relative risk parameters, and beta distribu-
tions for the treatment discontinuation rate parameters. We used the ranges stated for the probabilistic sensitivity analysis
Modelled strategy MAIC-based hazard ratio of 6-month confirmed 
disease progression vs placebo (range) [20]





Siponimod and BSC Comparatora is interferon beta-1a: 0.48 (0.22–
0.91)
Comparator is interferon beta-1b: 0.50 (0.31–
0.76)
Comparator is natalizumab: 0.80 (0.52–1.18)
Comparatora is interferon beta-1a: 0.50 (0.28–
0.83)
Comparator is interferon beta-1b: 0.59 (0.35–
0.93)
Comparator is natalizumab: 0.65 (0.38–1.04)
6.37% (5.18–7.67)
Comparator Comparatora is interferon beta-1a: 1.13 (0.81–
1.54)
Comparator is interferon beta-1b: 0.92 (0.70–
1.19)
Comparator is natalizumab: 1.06 (0.72–1.50)
Comparatora is interferon beta-1a: 0.69 (0.56–
0.84)
Comparator is interferon beta-1b: 0.65 (0.47–
0.87)
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2.7  Drug Acquisition and Administration
The price of siponimod used for the analysis was CHF 62.82 
per dose. This was based on a calculation derived from the 
Spezialitätenliste of the weighted average of the prices of 
a 1-mg dose (price of CHF 62.69) and a 2-mg dose (price 
of CHF 62.83) [9], and assuming a genotype that 10% of 
patients would receive a 1-mg dose and 90% receive a 2-mg 
dose. Siponimod is recommended to be administered daily 
until treatment is discontinued. The list price of interferon 
beta-1a was CHF 90.64 per 22-µg dose, obtained from the 
Spezialitätenliste in April 2020, with patients with SPMS 
indicated to receive interferon beta-1a as a 22-µg dose three 
times per week until treatment is discontinued.
Besides the cost of acquiring siponimod and interferon 
beta-1a, we included the costs of DMT administration and 
monitoring for the period in which the patients were pro-
jected to receive DMT (Table 3). Full details are provided 
in Tables A4-1 and A4-2 of the ESM. We calculated annual 
DMT administration and monitoring costs based on the 
unit costs of the relevant resource items multiplied by the 
estimated number of required resource items per year. We 
estimated unit costs for outpatient physician visits, tests and 
imaging procedures from the Swiss tariff systems for out-
patient physician services (TARMED) [32] and laboratory 
tests (Analysenliste) [33]. The Swiss clinical experts we 
consulted certified the validity of the assumptions we made 
about resource use items per year. The clinical experts were 
two neurologists based in Basel, Switzerland, who were each 
interviewed separately for 1 h each in 2019. We showed the 
neurologists a list of estimated resource use items and values 
for patients with SPMS, and the neurologists amended this 
list based on their experience of how patients with SPMS 
are routinely treated in Switzerland.
2.8  Disease Management Cost
Costs of disease management in each model cycle were 
incurred based on the proportion of patients in each EDSS 
state multiplied by the annual disease management costs 
associated with the EDSS state. We obtained annual disease 
management costs assigned to each EDSS-based health state 
from a publication by Calabrese et al. of Swiss patients with 
MS (and assumed to be the same for patients with active 
SPMS owing to a lack of SPMS or active SPMS-specific 
data; as the exchange with the Swiss clinical experts did 
not cover this, we varied this set of parameters in a scenario 
analysis) [21]. As the set of disease management costs by 
Calabrese et al. incorporated relapse costs, we reduced each 
of the cost estimates by 23% to take out the relapse costs. 
This fixed percentage was estimated from the same study, 
and we used it across all EDSS categories as the authors only 
reported overall resource use costs with and without relapses 
rather than relapse costs for each EDSS category.
For the entire period in which patients were alive in the 
model, they were assumed to additionally receive BSC at an 
annual cost of CHF 1748.66. The annual BSC cost was again 
obtained from Calabrese et al. (and assumed to be the same 
for patients with active SPMS in our analysis) [21].
2.9  Relapse Management
The cost of managing active SPMS relapses was also incor-
porated into the analysis. We used an estimate based on 
Calabrese et al. of CHF 4344.34 for managing a relapse in 
Swiss patients with MS. For our analysis, we multiplied this 
estimate by two as according to a Swiss clinical expert we 
consulted, the cost of managing an SPMS relapse is approxi-
mately twice as high as managing a relapse in a general 
Table 3  Model input parameters related to costs
CHF Swiss francs
For the probabilistic sensitivity analysis, we used log-normal distributions for cost parameters. Drug acquisition and genotype testing costs were 
not varied in the probabilistic sensitivity analysis
Costs Cost in CHF (range) Source
Siponimod drug cost (weighted average of 1-mg and 2-mg doses) 62.82 (50.26–75.38) Spezialitätenliste [9]
Siponimod administration and monitoring cost year 1 1237.37 (1012.58–1497.09) Analysenliste [33] and TARMED [32]
Siponimod administration and monitoring cost year 2 260.03 (212.79–314.60) Analysenliste [33] and TARMED [32]
Interferon beta-1a drug cost (per 22-µg dose) 90.64 (72.51–108.77) Spezialitätenliste [9]
Interferon beta-1a administration and monitoring cost year 1 903.79 (739.60–1,093.49) Analysenliste [33] and TARMED [32]
Interferon beta-1a administration and monitoring cost year 2 286.76 (234.67–346.95) Analysenliste [33] and TARMED [32]
Annual best supportive care cost 1748.66 (1430.99–2115.69) Calabrese et al. [21]
Genotype testing cost 227.05 (–) Analysenliste [33] and TARMED [32]
Relapse management cost 8689 (7110–10,512) Calabrese et al. [21], estimate doubled 
based on a clinical expert
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patient with MS. The clinical expert we consulted is a neu-
rologist based in Basel, Switzerland.
2.10  Adverse Event Costs
We included the costs of serious and non-serious adverse 
events in the analysis (Table A3-3 of the ESM). We obtained 
the proportions of patients experiencing each adverse event 
from the EXPAND trial for siponimod [18] and from the 
NICE single technology appraisal of ocrelizumab for inter-
feron beta-1a (Table A3-1 of the ESM) [27]. We multiplied 
each proportion by the associated unit costs of the adverse 
events, which we obtained from the Swiss DRG tariff data 
[34] for adverse events treated by hospitalisation, and from 
TARMED and Spezialitätenliste (i.e. the list of outpatient 
drugs reimbursed by the Swiss statutory health insurance) 
for adverse events treated by combined outpatient visits and 
prescription drug treatments [9, 32].
2.11  Sensitivity Analysis
We undertook one-way deterministic and probabilistic sensi-
tivity analyses. In the one-way sensitivity analysis, we varied 
each cost, EQ-5D, and effectiveness parameter to the lower 
and upper bound of its 95% CI, to assess the resulting impact 
on the ICER, and presented the results of the 23 most influ-
ential parameters in a Tornado diagram. For siponimod and 
interferon beta-1a acquisition costs, given the absence of a 
95% CI for these, we applied a 20% reduction and increase 
to these costs for the one-way sensitivity analyses. In the 
probabilistic sensitivity analysis, we generated 1000 simu-
lated ICERs based on the mean value, standard error and 
distribution assigned to all of the model input parameters 
(excepting the discount rate, genotype testing costs, drug 
acquisition costs and the cut-off EDSS score of 7 for receiv-
ing DMT). If an empirically estimated standard error for a 
model input parameter did not exist, we assumed it was 10% 
of the mean parameter value. The distribution types assigned 
to input parameters were: log-normal for hazard ratios, rela-
tive risks (including relapse rates for untreated patients) and 
costs, beta for EQ-5D scores and treatment discontinuation 
rates, and Dirichlet for the EDSS-based baseline distribution 
of patients and the transition probability matrix.
To address uncertainty about various model assumptions 
and parameters, we undertook various scenario analyses. 
We explored natalizumab and interferon beta-1a as alter-
native model comparators. We varied discount rates and 
time horizons of the model. Instead of using MAIC esti-
mates of treatment efficacy, we undertook a scenario analy-
sis where we used direct estimates from trials (including 
for the active SPMS subgroup in the EXPAND trial [18]) 
without a matching adjustment. A further scenario analysis 
was undertaken where a 3-month CDP outcome instead of 
a 6-month CDP outcome from the EXPAND trial was used 
to model transitions between EDSS-based health states for 
the siponimod treatment strategy. We also undertook a sce-
nario analysis using an (approximate) societal perspective 
that incorporated productivity losses due to short-term sick 
leave, and early retirement, which we extracted from Fig. 6 
in the study by Calabrese et al. by digitalising the figure [21]. 
This analysis may be considered to be an approximation of 
a societal perspective rather than a full societal perspective, 
as we did not include informal carer costs and disutilities in 
this scenario analysis (or in any of the other analyses). In a 
further scenario analysis, we assumed that disease manage-
ment costs are 1.5 times higher than were assumed for the 
base-case analysis.
2.12  Budget Impact Analysis
For the budget impact analysis, we adopted a 3-year time 
horizon and included costs of drug acquisition, drug admin-
istration and adverse events to estimate overall healthcare 
costs in Switzerland, comparing a situation where siponimod 
is approved with a situation where it is not approved. It was 
estimated that there are 1984 patients with active SPMS in 
Switzerland in 2021 (further details of how this was esti-
mated are provided in Section A5 of the ESM). The distri-
bution of patients across DMT classes (orals, injectables, 
infusions/no treatment), in the absence of siponimod, was 
estimated from an unpublished Novartis survey of 41 Swiss 
neurologists treating patients with MS. We recruited survey 
participants from office-based and hospital-based care set-
tings and across the different language regions of Switzer-
land. We used commercially available IQVIA sales data for 
Switzerland from February 2020 to estimate the individual 
treatments within treatment classes obtained from the sur-
vey. For the situation with siponimod approved, we assumed 
that 8% of Swiss patients with active SPMS would be taking 
siponimod in year 1, 17% in year 2 and 25% in year 3. A full 
description of the methods for the budget impact analysis is 
provided in the ESM (Section A5).
2.13  Model Validation
We used a hybrid checklist of published checklists to vali-
date the cost-effectiveness model. The model was found to 
be internally valid and externally valid. Internal validation 
of the model focused on the technical accuracy of the model 
and was intended to identify programming errors, data entry 
issues and logical inconsistencies in the model, which could 
then be corrected if identified. Therefore, we performed a 
variety of extensive tests before the model was used for the 
cost-effectiveness analysis. The aim of these tests was to 
demonstrate that the model was able to predict the results in 
a manner consistent with expectations. External validation 
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of the model focused on the face validity and cross validity 
of results. The outcomes generated by an early version of 
the model using inputs from a previously published cost-
effectiveness analysis of fingolimod for the UK [35] were 
compared to the results from the fingolimod analysis. Face 
validity of the model was assessed by discussing the model 
results with two UK MS practicing physicians, via Skype 
interviews using a pre-specified list of questions.
3  Results
For the base-case analysis, we estimated that the siponimod 
treatment strategy generated discounted mean incremental 
drug acquisition costs of CHF 102,633 (siponimod: CHF 
189,072, interferon beta-1a: CHF 86,438), mean incremen-
tal costs of the overall strategy of 84,901 (siponimod: CHF 
567,838, interferon beta-1a: CHF 482,937), mean incremen-
tal QALYs of 1.591 (siponimod: 7.495, interferon beta-1a: 
5.905) and mean incremental LYs of 0.484 (siponimod: 
18.896, interferon beta-1a: 18.412) (Table 4). This led to 
ICERs of CHF 53,364 per QALY gained and CHF 175,410 
per LY gained. The siponimod treatment strategy was pro-
jected to result in mean incremental undiscounted LYs of 
1.06 years (siponimod: 28.40, interferon beta-1a: 27.33). 
Higher drug acquisition costs in the siponimod strategy were 
to a limited extent compensated by lower disease manage-
ment and relapse costs.
For the scenario analysis where we adopted a societal 
perspective, siponimod was projected to be a dominant treat-
ment strategy (i.e. produce lower costs and higher QALYs 
than interferon beta-1a). For the analysis where the compara-
tor was natalizumab (rather than interferon beta-1a), siponi-
mod was estimated to be dominant. The scenario analysis 
where the primary endpoint used was 3 months of CDP 
(instead of 6 months) produced an ICER of CHF 136,514 
per QALY gained. Full secondary analysis results are pre-
sented in Table 5.
In the one-way deterministic sensitivity analysis (Fig. 2), 
we varied over 150 parameters. For the majority of these, 
this resulted in only small changes to the base-case ICER. 
Varying the siponimod hazard ratio of 6-month CDP to the 
lower and upper bound of its 95% CI resulted in ICERs of 
CHF 34,448 and CHF 154,640, respectively. Varying the 
interferon beta-1a hazard ratio of 6-month CDP to the lower 
and upper bound of its 95% CI resulted in ICERs of CHF 
74,540 and CHF 44,731, respectively. In the probabilistic 
sensitivity analysis, the siponimod treatment strategy was 
more cost effective than CHF 100,000 per QALY gained in 
90% of simulations (Fig. 3a, b).
In the budget impact analysis, the introduction of siponi-
mod for the treatment of active SPMS was projected to 
result in additional healthcare costs in Switzerland of CHF 
2,177,021 in the first 3 years after introduction (CHF 308,342 
in 2021, CHF 697,246 in 2022 and CHF 1,171,434 in 2023). 
The cost of CHF 2,177,021 over 3 years was generated from 
the estimated siponimod drug acquisition costs totalling to 
CHF 23,817,856, minus the displaced cost of acquiring other 
drugs totalling to CHF 19,179,912, with some additional 
adjustments to account for reduced drug administration and 
monitoring costs and adverse event costs estimated from the 
market introduction of siponimod. Full budget impact results 
are documented in Appendix A5 of the ESM.
Table 4  Discounted base-case 
results (Swiss statutory health 
insurance perspective)
BSC best supportive care, CHF Swiss Francs, LY life-years, QALY quality-adjusted life-years
Siponimod and 
BSC




 LYs 18.896 18.412 0.484
 QALYs 7.495 5.905 1.591
Cost parameters (CHF)
 Total costs 567,838 482,937 84,901
 Drug acquisition 189,072 86,438 102,633
 Drug administration and monitoring 2843 1821 1021
 Adverse events 456 1010 −555
 Disease management 340,304 352,985 −12,681
 Relapse 35,165 40,682 −5518
Incremental cost-effectiveness ratio
 Cost per (CHF) LY gained 175,410
 Cost per (CHF) QALY gained 53,364
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Table 5  Results of scenario analyses
CHF Swiss Francs, ICER incremental cost-effectiveness ratio, MAIC matching-adjusted indirect comparison, QALYs quality-adjusted life-years




ICER (CHF per 
QALY gained)
Base-case analysis CHF 84,901 1.591 CHF 53,364
Discount rate: 0% for costs and outcomes CHF 117,916 2.540 CHF 46,422
Discount rate: 2% for costs and outcomes CHF 93,673 1.841 CHF 50,882
Discount rate: 6% for costs and outcomes CHF 66,565 1.082 CHF 61,546
Time horizon: 5 years CHF 33,284 0.200 CHF 166,667
Time horizon: 10 years CHF 52,988 0.548 CHF 96,623
Time horizon: 20 years CHF 71,671 1.152 CHF 62,199
Time horizon: 50 years CHF 84,900 1.591 CHF 53,364
Societal perspective −CHF 11,770 1.59 Dominant
Primary endpoint is 3 months of confirmed disability progression CHF 67,814 0.497 CHF 136,514
Non-MAIC-based effectiveness CHF 76,751 1.076 CHF 71,326
Alternative model comparator assumed: natalizumab −CHF 101,967 0.598 Dominant
Alternative model comparator assumed: interferon beta-1b CHF 74,939 1.192 CHF 62,872
Disease management costs were 1.5 times higher than in the base case CHF 78,560 1.591 CHF 49,378
Fig. 2  Tornado diagram of deterministic sensitivity analysis results: 
the most influential model parameters. The cost effectiveness of the 
siponimod strategy vs the interferon beta-1a strategy is assessed in 
the figure. The base-case incremental cost-effectiveness ratio (ICER) 
of Swiss Francs (CHF) 53,364 per quality-adjusted life-year gained is 
represented by the vertical line in the graph. Additional information 
on the parameters and their respective bounds is provided in Table A6 
of the ESM. DMT disease-modifying therapy, EDSS Expanded Dis-
ability Status Scale
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Fig. 3  Cost-effectiveness plane (a) and acceptability curve (b). CHF Swiss Francs, QALYs quality-adjusted life-years
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4  Discussion
The cost effectiveness of siponimod has previously been 
researched and published in the USA [8], the UK [28] and 
Canada [36], and has been approved for use in adult patients 
with SPMS with active disease in all three settings. In the 
USA and Canada, it was found that siponimod was unlikely 
to be a cost-effective treatment for adult patients with SPMS 
with active disease at the list prices that were originally pro-
posed for these countries. The assessment for the USA was 
based on a much higher proposed price of siponimod than 
in this analysis. In the UK, siponimod was considered likely 
to be cost effective, and was approved by NICE following a 
confidential price reduction to the siponimod list price. Our 
research found siponimod is likely to be cost effective in 
Switzerland when priced at CHF 62.69 per 1-mg dose and 
CHF 62.83 per 2-mg dose, if assuming a cost-effectiveness 
threshold of CHF 100,000 per QALY gained, as it produced 
an ICER of CHF 53,364 per QALY gained. Although there 
are no formal guidelines specifying what threshold should 
be used for cost-utility analyses in Switzerland, a thresh-
old of CHF 100,000 per QALY gained has been considered 
in previously published analyses. We found that an ICER 
below CHF 100,000 per QALY gained was maintained in 
the majority of sensitivity and scenario analyses undertaken. 
Our base-case analysis used CDP at least 6 months after the 
previous assessment (6-month CDP), as the basis for esti-
mating the efficacy of siponimod for the cost-effectiveness 
analysis. Confirmed disability progression after 3 months 
(which was the primary outcome of the EXPAND trial) 
is considered a less robust efficacy measure of permanent 
disability progression than progression confirmed after 
6 months, as the time taken to recover from a relapse varies 
and people may not recover from a relapse after 3 months. 
Furthermore, longer observation periods are preferable 
over shorter periods, as they reduce the uncertainties aris-
ing from extrapolation to the time horizons required for a 
cost-effectiveness analysis, provided there is no substantially 
increased risk of attrition bias. There was no difference in 
sample size between the 3-month CDP and 6-month CDP 
outcomes in the EXPAND trial for siponimod, indicating no 
additional risk of attrition bias as a result of using 6-month 
CDP. Six-month CDP was the only CDP outcome that was 
measured in the Nordic SPMS trial for interferon beta-1a. 
When we adopted the approach of using CDP after 3 months 
in a scenario analysis, a much higher ICER of CHF 136,514 
per QALY gained for siponimod was estimated.
There were several limitations to our study. Effects were 
seen during a limited clinical trial observation period, and 
were applied in the long term. This implies an assump-
tion of continued treatment effect. Disability progres-
sion transition probabilities between EDSS levels do not 
reflect transition probabilities between EDSS levels that 
changed as a result of confirmed disability progression. 
A similar limitation is also applicable to the previous 
cost-effectiveness models in the literature. The compara-
tor for the base-case cost-effectiveness analysis we per-
formed was interferon beta-1a, although there are other 
comparators that may be used in Switzerland for patients 
with SPMS such as interferon beta-1b and natalizumab, 
which we compared with siponimod in scenario analyses. 
Furthermore, fingolimod was not used as a comparator in 
the analysis, as although it is a frequently used treatment 
for MS in Switzerland, a relevant trial for fingolimod for 
SPMS was not identified in the systematic review by Sam-
joo et al. [20]. The EXPAND trial recruited patients with 
baseline EDSS scores from 3.0 to 6.5, thus our results 
may not generalise to patient with active SPMS outside 
of this range of EDSS scores. We estimated the clinical 
effectiveness of interferon beta-1a based on data from a 
single randomised controlled trial that reported no effect 
of interferon beta-1a on disability progression [37]. How-
ever, other randomised controlled trials have found slightly 
more positive evidence of a reduction in disability progres-
sion from treatment with beta‐1a or beta‐1b interferons 
[38]. To address this limitation, we carried out a scenario 
analysis using interferon beta-1b as a comparator. Because 
of the absence of available MAIC results for active SPMS, 
we used hazard ratios for 6-month CDP and relative risks 
of relapse estimated for patients with SPMS regardless of 
subtype, and assumed these were applicable to the active 
SPMS subtype. To address the limitation, we undertook 
a scenario analysis using results directly reported from 
the EXPAND trial of participants with active SPMS and 
without a matching adjustment [18], which has the limita-
tion that differences in the baseline characteristics of the 
study populations are not accounted for. This approach 
produced a slightly less favourable ICER of CHF 71,326 
per QALY gained. In the budget impact analysis, there was 
an inherent uncertainty about market uptake over the first 
3 years. The size of the active SPMS population is subject 
to uncertainty because of the nature of the disease. Patients 
gradually transition from RRMS to SPMS, limiting exact 
estimates of the number of patients. The diagnosis of 
SPMS/active SPMS is hindered by the relatively small 
number of DMTs approved in this indication as opposed to 
RRMS. Consequently, neurologist feedback was required 
to estimate DMT use in the siponimod target population. 
Nevertheless, these limitations are not expected to strongly 
affect the budget impact of the introduction of siponimod 
as a high rate of patients with MS currently receive DMT 
and remain taking treatment when transitioning to SPMS. 
It is thus expected that a large proportion of patients would 
transition from a currently reimbursed DMT to Siponimod, 
resulting in budget offsets.
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5  Conclusions
Our base-case analysis indicates that siponimod may be 
a cost-effective treatment for patients with active SPMS. 
Related uncertainty of all the results provided is unavoid-
able given the lack of head-to-head trials directly comparing 
siponimod with other active treatments. The results of the 
cost-effectiveness analyses are valid under the assumption 
that the efficacy of siponimod and the comparators on dis-
ability progression for the overall SPMS population would 
be the same in the active SPMS population. Siponimod is 
expected to replace different treatments with indications 
in RRMS and SPMS, offsetting a large proportion of the 
siponimod costs. This indicates siponimod may be afford-
able to healthcare payers in Switzerland.
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